A retrospective study to compare functional and anatomic treatment outcomes with intravitreal aflibercept versus bevacizumab and/or ranibizumab in patients with recurrent macular edema (ME) secondary to central retinal vein occlusion (CRVO)
Latest Information Update: 18 Oct 2019
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
Most Recent Events
- 18 Oct 2019 New trial record